They found that α7 nAChR activation increases STAT3 phosphorylation, decreases TNF-α and IL-6 expressions, and ultimately reduces viral myocarditis, indicating that α7 nAChR agonists could be a promising new strategy for patients with viral myocarditis. This evidence concerns the gene CHRNA7 and viral myocarditis.